Skip to main content
All articles

Site Operations

Benchmarking the fees nobody publishes: screen-fail, unscheduled visits, and post-lock queries

By Julio G. Martinez-Clark Published November 6, 2026 Updated November 6, 2026 7 min read

Why these three fees stay invisible

Most budget discussion focuses on the per-patient visit schedule, because it is visible in the protocol. These three items live outside it. They are conditional events: they happen only when a candidate does not qualify, when a participant needs attention between planned visits, or when a sponsor's data team raises a question after database lock.

Because they are conditional, sponsors tend to price them as afterthoughts: a flat allowance, a token line, or nothing at all. Because they are irregular, sites tend to accept whatever is offered rather than cost them properly. That is why no trustworthy benchmark exists. The work is real and skilled; it simply happens off the visit grid, and off-grid work is easy to underprice until your team is doing it unpaid.

I run Amavita Research Services, a Miami cardiovascular trial site with more than 18,000 active cardiology patients and zero Food and Drug Administration (FDA) Form 483 findings, and I am also chief executive officer (CEO) of bioaccess, a first-in-human contract research organization (CRO). The lesson across both roles: a fee that cannot be traced to named work will not survive negotiation.

Start with the work, not with the market

A defensible fee is a costed build-up. For each event, list every task it triggers, name who performs it, estimate the time it takes in real conditions, and attach your internal cost for that time and those resources. The building blocks are usually the same:

  • Coordinator time to schedule, prepare, conduct, and close out the event
  • Principal investigator (PI) review, judgment, and signature where the event requires medical oversight
  • Laboratory and phlebotomy work, including sample handling and processing
  • Source documentation: the original records that prove what was done
  • Data entry into the electronic data capture (EDC) system, plus the query handling that follows

Add direct costs where they apply, such as laboratory kits, record retrieval, and storage. Then test the total against your own records from recent studies; if estimate and history disagree, trust your history and find out why. That reconciled build-up, documented on one page, is your benchmark — one you can explain line by line to a sponsor without bluffing.

Screen failures: price the full screening effort

A screen failure is not a short visit that went wrong. It is a nearly complete work-up that produces no enrolled participant. The coordinator has usually obtained informed consent, recorded medical history, coordinated assessments, drawn blood, arranged testing, and documented eligibility criterion by criterion. The PI has reviewed the results and made the eligibility decision. The team has entered the data, answered queries, and filed the source documents for a person who will never generate a per-patient visit payment.

So follow the screening pathway step by step, from consent through the final eligibility determination, and cost each step your site actually performs before the failure is declared. Do not cost steps the sponsor performs or your site never reaches. Precision is what makes the number credible.

The budget exhibit in your clinical trial agreement (CTA) also needs a precise definition. State what counts as a screen failure: a consented candidate who completes any protocol-required screening procedure and is then determined ineligible, withdraws before enrollment, or is not enrolled for a protocol-defined reason. State when the fee is triggered, what documentation supports it, and whether partial work is paid when a candidate stops partway through. Without that definition, sites and sponsors argue about individual cases months later, when memories are thin.

Unscheduled visits: define when extra care becomes billable work

Unscheduled visits cover everything from a participant who reports a new symptom to a repeat laboratory draw, a blood pressure recheck, or an additional assessment after a result comes back out of range. The clinical duty is not in question: if a participant needs attention, the site provides it. The commercial question is narrower — which visits are already covered inside the per-patient fee, and which are additional work that should be billed?

Build the fee the same way. Itemize a typical visit: coordinator time to triage and schedule, room and staff time, PI or qualified clinician review, laboratory or phlebotomy work, source documentation, EDC entry, and follow-up communication with the participant and the sponsor's medical team. If visits vary widely in intensity, cost more than one tier internally, so you know your true range even if you negotiate a single fee.

Then define billability in the exhibit: an unscheduled visit is billable when it occurs outside the protocol visit schedule, requires site resources beyond a brief telephone contact, and is documented in a source note. State what is excluded, such as a short scheduling call, who can request or approve the visit, and how quickly it must be reported. The sponsor is not billed for trivial contact, and the site is not absorbing full clinical visits for free.

Post-lock queries: work that arrives after everyone has moved on

Database lock is supposed to mark the end of data cleaning. In practice, questions surface afterward during analysis and regulatory review, and they come back to the site. A post-lock query can require retrieving archived source documents, locating staff who worked on the study, reconstructing a visit long past, obtaining a PI attestation, and documenting the answer so it withstands later inspection.

That is senior, careful work, arriving at the worst possible time: after the study team has been reassigned and the budget is considered closed. Cost it honestly — record retrieval and archive handling, coordinator time to research the question, PI time to review and attest, and documentation and transmission of the response. Keep any storage charges separate and visible rather than burying them in this line.

Definition matters most here. The exhibit should state what a post-lock query is, when the post-lock period begins, how queries will be delivered, what response format is required, and whether the fee applies per query, per participant record reviewed, or per hour of documented work. Per-query pricing fails when one query takes minutes and the next takes an afternoon of archive digging. A structure tied to documented time, or a per-query fee with a defined scope and a route for exceptional effort, is fairer to both sides.

Use cap-and-review structures instead of silent exposure

Sponsors resist open-ended conditional fees because their budgets need ceilings. Sites resist hard caps because event volume is outside their control. Cap-and-review language bridges that gap: agree on a cap, paired with a review trigger. When activity reaches the cap, both sides review actual counts, revisit the assumptions, and adjust in writing if the study's real pattern differs from the plan.

This replaces suspicion with data. The sponsor gets protection against runaway costs; the site gets a contractual moment to reopen the conversation before unpaid work accumulates, rather than a dispute at close-out. Record the counts as you go: a site that arrives with a clean log of events, dates, and effort has a short conversation.

Compare sponsors against your build-up, not against each other

Once your build-up exists, comparison is straightforward. When a sponsor offers a screen-fail fee, an unscheduled visit fee, or post-lock terms, measure the offer against your costed work. Where it covers the work, say so and move on. Where it does not, show the gap line by line: this task, this role, this time, this cost. Sponsors can argue with a demand for more money; they have a much harder time arguing with an itemized account of work their own protocol requires.

Keep every build-up you prepare. Over several studies, they become your private benchmark library, grounded in actual experience rather than numbers nobody can source. It tells you what you need at the negotiating table: what the work costs you, stated clearly enough that a fair sponsor can say yes.

Next step

Sponsors: see what Amavita Research can run

Amavita Research is a Miami cardiovascular trial site with 18,000+ active cardiology patients and zero United States Food and Drug Administration (FDA) Form 483 findings. See our site capabilities or talk with our sponsor team.

By Julio G. Martinez-Clark · Last updated November 6, 2026. This article is site-operations education and is not medical advice or a regulatory recommendation.

AI assistant, not a human. Please do not include health information.